Objective: To observe the clinical effect of tongxinluo capsules in the treatment of diabetic peripheral neuropathy.
Methods: A total of 132 patients with diabetic peripheral neuropathy in our hospital from June 2014 to June 2017 were selected as subjects. Using a random even-odd number method, the patients were divided into control (n=66) and treatment (n=66) groups. The patients in the control group were treated with mecobalamin, whereas the patients in the treatment group were treated with tongxinluo capsules. Clinical efficacy, blood glucose level change, electromyography nerve conduction velocity, and clinical signs of improvement were compared before and after treatment.
Results: The total effective rate was significantly higher in the treatment group than in the control group (P<0.05). Meanwhile, the fasting blood glucose, postprandial 2 h blood glucose, and glycosylated hemoglobin levels were significantly lower in the treatment group than in the control group (P<0.05). Moreover, motor and sensory nerve conduction velocities were significantly higher in the treatment group than in the control group (P<0.05). The total effective rate of clinical symptom improvement was significantly lower in the treatment group than in the control group (P<0.05).
Conclusion: Tongxinluo capsules can alleviate clinical symptoms, as well as improve therapeutic effects, blood glucose levels, and nerve conduction velocity, in patients with diabetic peripheral neuropathy. The capsules can be used as an ideal drug and merits popularization.Author(s): Qian Xiao, Fang Liu, Qian Zhao, Feng Chen, Yong Zhou